This website sets cookies which are used to offer a personalized experience on our website, generate statistics, and realize advertising or social network tracking. Find out more about our Privacy & Cookie policy and how to manage them on your browser. You can change your cookie settings at any time.

Industry Supported Educational Sessions 

Friday May 13th:

Lunch Symposium 12:15pm – 1:00pm

In Governor General I

Title: Refining NAFLD/NASH Patient Referrals to Liver Specialists in Canada Using Non-Invasive Tests such as the Siemens Healthineers ELF Score

Speaker: Dr. Youssef Maakaroun

Description: In this Industry Symposium, the speaker will explore different diagnostic and care pathways from other parts of the world in order to increase awareness on Non-Invasive serum markers and how they can be used to refine NAFLD/NASH patient referrals to liver specialists. In Canada, NAFLD prevalence was estimated at 25% in 2018 impacting close to 8 million people. Blood-based tests can readily support high-volume testing, do not require patient access to specialized imaging equipment or highly trained operators, and generally have lower incidence rates of failure and unreliable results reported for imaging modalities. Incorporating a fast and simple blood test can help enhance patient management with a test that has been shown to outperform biopsy for the risk assessment of progression to cirrhosis and liver-related clinical events (LREs).

 

Saturday May 14th:

Breakfast Symposium 7:00am – 8:00am

In Governor General I

Title: Meet the Experts: Discuss Practical Considerations for Managing HCV in People Who Use Drugs

Moderator: Dr. Hemant Shah, Francis Family Liver Clinic, Toronto General Hospital, University of Toronto, Canada

Spreakers: Dr. Chris Fraser, Cool Aid Community Health Centre, UBC Faculty of Medicine, Canada, Dr. Alain Litwin, Vice-Chair of Academics and Research, Department of Medicine Prisma Health, USA & Bernadette Lettner RN, Toronto Community Hepatitis C Program, Canada

Description: A multi-disciplinary panel of experts will examine Hepatitis C in the people who use drugs population and address common challenges with HCV treatment and adherence.

 

Sponsor Spotlight 10:15AM – 10:45AM

virtual

Title: “Observe and Report” - Latest updates and research from CaNAL

Speakers: Dr. Aliya Gulamhusein, Toronto Centre for Liver Disease - Toronto General Hospital, University Health Network, Canada & Dr. Aldo Montano-Loza, University of Alberta, Canada

 

Lunch Symposium 11:30am – 12:30pm

In Governor General I

Title: The Inside Report

Speaker: Dr. Hemant Shah, Francis Family Liver Clinic, Toronto General Hospital, University of Toronto, Canada

Objectives:

  • Describe common barriers to care and strategies that can be applied to address them
  • Determine who to screen for hepatitis C virus (HCV), and apply new diagnostic methods to identify patients who are viremic and therefore require treatment
  • Examine practical aspects relating to the treatment of patients including priority populations, and/or complex clinical scenarios
  • Review data on efficacy and safety of available treatments for HCV in targeted populations
  • Implement current guidelines in clinical practice to simplify and optimize HCV treatment

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and approved by the Canadian Association for the Study of Liver.  Participants can claim up to a maximum of 1.0 study credits.

This education program was co-developed by CASL and AbbVie, and planned to ensure scientific integrity, objectivity, and balance.

 

Sunday may 15th:

BREAKFAST SYMPOSIUM 7:00am – 8:00am

In Governor General I

Title: Disrupting the Current Landscape Towards an Earlier Diagnosis of Chronic Liver Disease

Speakers: Dr. Mayur Brahmania, Western University, Canada & Dr. Varinder Athwal, University of Manchester, UK

Objectives: 

  • Appreciate the need for early detection and diagnosis of liver disease and HCC in Canada
  • Examine innovative approaches to early detection of liver disease and HCC
  • Describe how multimodal diagnostics and data science is being employed in the IDLiver project (Manchester, UK) to improve early diagnosis and stratification of liver disease